Celldex Therapeutics, Inc.
CLDX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.64 | -0.63 | -0.40 | 1.25 |
| FCF Yield | -9.81% | -5.68% | -5.05% | -3.75% |
| EV / EBITDA | -8.35 | -13.59 | -19.81 | -24.52 |
| Quality | ||||
| ROIC | -25.81% | -35.31% | -34.19% | -16.45% |
| Gross Margin | 100.00% | -1,614.53% | -3,389.94% | 34.04% |
| Cash Conversion Ratio | 1.00 | 0.76 | 0.92 | 0.86 |
| Growth | ||||
| Revenue 3-Year CAGR | 43.88% | 13.96% | -31.76% | 9.19% |
| Free Cash Flow Growth | -46.36% | -3.36% | -69.83% | -48.15% |
| Safety | ||||
| Net Debt / EBITDA | 0.13 | 0.23 | 0.24 | 0.55 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -4.03 | -17.84 |
| Cash Conversion Cycle | -338.71 | -284.61 | -907.52 | -153.06 |